ASM Microbe Conference

Alan Gross, PharmD, shares how an early diagnosis of multidrug-resistant pneumonia can work towards improving patient outcomes.

Milena McLaughlin, PharmD, MSc, explains how officials test if a drug is counterfeit or active.

Meghan Jeffres, PharmD, shares what should be considered when considering the incorporation of penicillin skin testing into a health care facility.

Alan Gross, PharmD, BCPS-AQID, shares how the Society of Infectious Diseases Pharmacists is working to improve antibiotic stewardship programs in long-term care facilities.

Julian Hurdle, PhD, explains research focused on validating FabK as an essential enzyme to be used as a narrow-spectrum drug target against Clostridium difficile.

Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.

Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.

Milena McLaughlin, PharmD, MSc, explains how antimicrobial shortages differ between high- and low-income countries.

Meghan Jeffres, PharmD, discusses the legal liability of prescribing beta-lactams to patients who are allergic to penicillin.

ason Gallagher, PharmD, BCPS FCCP, FIDSA, explains why clinicians should be aware of the challenges associated with getting antimicrobial susceptibility testing results.

Jason Pogue, PharmD, BCPS-ID, explains how ceftolozane-tazobactam differs from other beta-lactams for treating Pseudomonas infections.

Milena McLaughlin, PharmD, MSc, explains ways to remain vigilant when it comes to drug shortages.

Elizabeth Phillips, MD, FRCPC, FRACP, addresses the misconceptions about penicillin allergies.

Meghan Jeffres, PharmD, discusses the utility of penicillin skin testing for patients labeled as penicillin allergic.

Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.

Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.

Jason Pogue, PharmD, BCPS-ID, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.

Milena McLaughlin, PharmD, MSc, explains the best way to determine an alternative agent during a drug shortage.

Caetano Sabino, BSc, discusses how antimicrobial photodynamic therapy could be used to complement antimicrobial chemotherapy in order to manage drug-resistant infections.

Jason Gallagher, PharmD, BCPS, FCCP, FIDSA, explains how restrictions on commercial automated susceptibility testing can affect patient care.

Kenneth Mayer, MD, discusses new therapies that may have a positive impact on pre-exposure prophylaxis adherence and treatment.

Benjamin Young, MD, PhD, explains the Fast-Track Cities initiative.

Caetano P. Sabino, BSc, PhD Student, explains if photodynamic therapy a cost-effective treatment option.

Meghan Jeffres, PharmD, explains the importance of discussing cross-reactivity among beta-lactams.

Otto Schwake, PhD, discusses the findings of his team’s study exploring Legionella in car washer fluid.

Milena McLaughlin, PharmD, MSc, explains different strategies institutions can take to obtain antimicrobials that are on shortage.

Jason Pogue, PharmD, BCPS-ID, explains the limitations of the current drugs for the treatment of Pseudomonas aeruginosa infections.

Caetano Sabino, BSc, explains how photodynamic therapy can be used to challenge microbial resistance of localized infections.

Conan MacDougall, PharmD, explains what individuals should consider when it comes to adopting interventions in antibiotic stewardship programs.